These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 14503959

  • 1. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy.
    Harris TD, Kalogeropoulos S, Nguyen T, Liu S, Bartis J, Ellars C, Edwards S, Onthank D, Silva P, Yalamanchili P, Robinson S, Lazewatsky J, Barrett J, Bozarth J.
    Cancer Biother Radiopharm; 2003 Aug; 18(4):627-41. PubMed ID: 14503959
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Structure-activity relationships of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents.
    Harris TD, Kalogeropoulos S, Nguyen T, Dwyer G, Edwards DS, Liu S, Bartis J, Ellars C, Onthank D, Yalamanchili P, Heminway S, Robinson S, Lazewatsky J, Barrett J.
    Bioconjug Chem; 2006 Aug; 17(5):1294-313. PubMed ID: 16984141
    [Abstract] [Full Text] [Related]

  • 4. 90Y and 111In complexes of a DOTA-conjugated integrin alpha v beta 3 receptor antagonist: different but biologically equivalent.
    Onthank DC, Liu S, Silva PJ, Barrett JA, Harris TD, Robinson SP, Edwards DS.
    Bioconjug Chem; 2004 Aug; 15(2):235-41. PubMed ID: 15025518
    [Abstract] [Full Text] [Related]

  • 5. Radiolabeled high affinity peptidomimetic antagonist selectively targets alpha(v)beta(3) receptor-positive tumor in mice.
    Jang BS, Lim E, Hee Park S, Shin IS, Danthi SN, Hwang IS, Le N, Yu S, Xie J, Li KC, Carrasquillo JA, Paik CH.
    Nucl Med Biol; 2007 May; 34(4):363-70. PubMed ID: 17499725
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
    Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, Rajopadhye M, Boonstra H, Corstens FH, Boerman OC.
    Cancer Res; 2002 Nov 01; 62(21):6146-51. PubMed ID: 12414640
    [Abstract] [Full Text] [Related]

  • 8. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
    Yoshimoto M, Ogawa K, Washiyama K, Shikano N, Mori H, Amano R, Kawai K.
    Int J Cancer; 2008 Aug 01; 123(3):709-15. PubMed ID: 18498129
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature.
    Shin IS, Jang BS, Danthi SN, Xie J, Yu S, Le N, Maeng JS, Hwang IS, Li KC, Carrasquillo JA, Paik CH.
    Bioconjug Chem; 2007 Aug 01; 18(3):821-8. PubMed ID: 17375899
    [Abstract] [Full Text] [Related]

  • 12. Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
    Mousa SA, Mohamed S, Wexler EJ, Kerr JS.
    Anticancer Res; 2005 Aug 01; 25(1A):197-206. PubMed ID: 15816539
    [Abstract] [Full Text] [Related]

  • 13. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
    Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, Chen X.
    J Nucl Med; 2007 Jul 01; 48(7):1162-71. PubMed ID: 17574975
    [Abstract] [Full Text] [Related]

  • 14. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
    Dijkgraaf I, Kruijtzer JA, Frielink C, Corstens FH, Oyen WJ, Liskamp RM, Boerman OC.
    Int J Cancer; 2007 Feb 01; 120(3):605-10. PubMed ID: 17096340
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
    Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M.
    J Nucl Med; 2001 Feb 01; 42(2):326-36. PubMed ID: 11216533
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
    Carron CP, Meyer DM, Pegg JA, Engleman VW, Nickols MA, Settle SL, Westlin WF, Ruminski PG, Nickols GA.
    Cancer Res; 1998 May 01; 58(9):1930-5. PubMed ID: 9581835
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
    Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X.
    Cancer Res; 2006 Oct 01; 66(19):9673-81. PubMed ID: 17018625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.